Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colin Glover

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Neuron|April 29, 2008
Expression of long-term depression underlies visual recognition memorySarah Griffiths, Helen Scott, Colin Glover, et al.
JCO Precision Oncology|September 16, 2021
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)Haider Mahdi, Navid Hafez, Deborah Doroshow, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 12, 2019
IL-22 Binding Protein Promotes the Disease Process in Multiple SclerosisHannes Lindahl, André O Guerreiro-Cacais, Sahl Khalid Bedri, et al.
Cancer|March 11, 2026
Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trialDeborah B Doroshow, Geoffrey I Shapiro, Khanh Do, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Neuron|April 29, 2008
Expression of long-term depression underlies visual recognition memorySarah Griffiths, Helen Scott, Colin Glover, et al.
JCO Precision Oncology|September 16, 2021
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)Haider Mahdi, Navid Hafez, Deborah Doroshow, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 12, 2019
IL-22 Binding Protein Promotes the Disease Process in Multiple SclerosisHannes Lindahl, André O Guerreiro-Cacais, Sahl Khalid Bedri, et al.
Cancer|March 11, 2026
Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trialDeborah B Doroshow, Geoffrey I Shapiro, Khanh Do, et al.
Pageof 1